Reorganization of MetastamiRs in the Evolution of Metastatic Aggressive Neuroblastoma Cells

Overview

Journal BMC Genomics

Publisher Biomed Central

Specialty Genetics

Date 2015 Jul 8

PMID 26148557

Citations 21

Authors

Faizan H Khan

Vijayabaskar Pandian

Satishkumar Ramraj

Sheeja Aravindan

Terence S Herman

Natarajan Aravindan

Affiliations

Soon will be listed here.

Abstract

Background: MetastamiRs have momentous clinical relevance and have been correlated with disease progression in many tumors. In this study, we identified neuroblastoma metastamiRs exploiting unique mouse models of favorable and high-risk metastatic human neuroblastoma. Further, we related their deregulation to the modulation of target proteins and established their association with clinical outcomes.

Results: Whole genome miRNA microarray analysis identified 74 metastamiRs across the manifold of metastatic tumors. RT-qPCR on select miRNAs validated profile expression. Results from bio-informatics across the ingenuity pathway, miRCancer, and literature data-mining endorsed the expression of these miRNAs in multiple tumor systems and showed their role in metastasis, identifying them as metastamiRs. Immunoblotting and TMA-IHC analyses revealed alterations in the expression/phosphorylation of metastamiRs' targets, including ADAMTS-1, AKT1/2/3, ASK1, AURKβ, Birc1, Birc2, Bric5, β-CATENIN, CASP8, CD54, CDK4, CREB, CTGF, CXCR4, CYCLIN-D1, EGFR, ELK1, ESR1, CFOS, FOSB, FRA, GRB10, GSK3β, IL1α, JUND, kRAS, KRTAP1, MCP1, MEGF10, MMP2, MMP3, MMP9, MMP10, MTA2, MYB, cMYC, NF2, NOS3, P21, pP38, PTPN3, CLEAVED PARP, PKC, SDF-1β, SEMA3D, SELE, STAT3, TLR3, TNFα, TNFR1, and VEGF in aggressive cells ex vivo and in a manifold of metastatic tumors in vivo. miRNA mimic (hsa-miR-125b, hsa-miR-27b, hsa-miR-93, hsa-miR-20a) and inhibitor (hsa-miR-1224-3p, hsa-miR-1260) approach for select miRNAs revealed the direct influence of the altered metastamiRs in the regulation of identified protein targets. Clinical outcome association analysis with the validated metastamiRs' targets corresponded strongly with poor overall and relapse-free survival.

Conclusions: For the first time, these results identified a comprehensive list of neuroblastoma metastamiRs, related their deregulation to altered expression of protein targets, and established their association with poor clinical outcomes. The identified set of distinctive neuroblastoma metastamiRs could serve as potential candidates for diagnostic markers for the switch from favorable to high-risk metastatic disease.

Citing Articles

An Engineered Prussian Blue Nanoparticles-based Nanoimmunotherapy Elicits Robust and Persistent Immunological Memory in a TH-MYCN Neuroblastoma Model.

Shukla A, Cano-Mejia J, Andricovich J, Burga R, Sweeney E, Fernandes R Adv Nanobiomed Res. 2021; 1(8).

PMID: 34435194 PMC: 8382205. DOI: 10.1002/anbr.202100021.

An EBC/Plasma miRNA Signature Discriminates Lung Adenocarcinomas From Pleural Mesothelioma and Healthy Controls.

Faversani A, Favero C, Dioni L, Pesatori A, Bollati V, Montoli M Front Oncol. 2021; 11:643280.

PMID: 34211838 PMC: 8239300. DOI: 10.3389/fonc.2021.643280.

Sevoflurane inhibits cell proliferation and migration of glioma by targeting the miR‑27b/VEGF axis.

Zhan X, Lei C, Yang L Mol Med Rep. 2021; 23(6).

PMID: 33786635 PMC: 8025459. DOI: 10.3892/mmr.2021.12047.

Glutaminase isoforms expression switches microRNA levels and oxidative status in glioblastoma cells.

De Los Santos-Jimenez J, Campos-Sandoval J, Marquez-Torres C, Urbano-Polo N, Brondegaard D, Martin-Rufian M J Biomed Sci. 2021; 28(1):14.

PMID: 33610185 PMC: 7897386. DOI: 10.1186/s12929-021-00712-y.

A survey of transcripts generated by spinal muscular atrophy genes.

Singh N, Ottesen E, Singh R Biochim Biophys Acta Gene Regul Mech. 2020; 1863(8):194562.

PMID: 32387331 PMC: 7302838. DOI: 10.1016/j.bbagrm.2020.194562.

References

Kawa K, Ohnuma N, Kaneko M, Yamamoto K, Etoh T, Mugishima H . Long-term survivors of advanced neuroblastoma with MYCN amplification: A report of 19 patients surviving disease-free for more than 66 months. J Clin Oncol. 1999; 17(10):3216-20. DOI: 10.1200/JCO.1999.17.10.3216. View

Cohn S, London W, Huang D, Katzenstein H, Salwen H, Reinhart T . MYCN expression is not prognostic of adverse outcome in advanced-stage neuroblastoma with nonamplified MYCN. J Clin Oncol. 2000; 18(21):3604-13. DOI: 10.1200/JCO.2000.18.21.3604. View

Natarajan M, Aravindan N, Meltz M, Herman T . Post-translational modification of I-kappa B alpha activates NF-kappa B in human monocytes exposed to 56Fe ions. Radiat Environ Biophys. 2002; 41(2):139-44. DOI: 10.1007/s00411-002-0143-x. View

Brodeur G . Neuroblastoma: biological insights into a clinical enigma. Nat Rev Cancer. 2003; 3(3):203-16. DOI: 10.1038/nrc1014. View

Schmidt-Kittler O, Ragg T, Daskalakis A, Granzow M, Ahr A, Blankenstein T . From latent disseminated cells to overt metastasis: genetic analysis of systemic breast cancer progression. Proc Natl Acad Sci U S A. 2003; 100(13):7737-42. PMC: 164657. DOI: 10.1073/pnas.1331931100. View

Weiss B, Vora A, Huberty J, Hawkins R, Matthay K . Secondary myelodysplastic syndrome and leukemia following 131I-metaiodobenzylguanidine therapy for relapsed neuroblastoma. J Pediatr Hematol Oncol. 2003; 25(7):543-7. DOI: 10.1097/00043426-200307000-00009. View

Bartel D . MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004; 116(2):281-97. DOI: 10.1016/s0092-8674(04)00045-5. View

Lau L, Tai D, Weitzman S, Grant R, Baruchel S, Malkin D . Factors influencing survival in children with recurrent neuroblastoma. J Pediatr Hematol Oncol. 2004; 26(4):227-32. DOI: 10.1097/00043426-200404000-00003. View

Cohn S, Tweddle D . MYCN amplification remains prognostically strong 20 years after its "clinical debut". Eur J Cancer. 2004; 40(18):2639-42. DOI: 10.1016/j.ejca.2004.07.025. View

10.

Kim V . MicroRNA biogenesis: coordinated cropping and dicing. Nat Rev Mol Cell Biol. 2005; 6(5):376-85. DOI: 10.1038/nrm1644. View

11.

Christofori G . New signals from the invasive front. Nature. 2006; 441(7092):444-50. DOI: 10.1038/nature04872. View

12.

Gupta G, Massague J . Cancer metastasis: building a framework. Cell. 2006; 127(4):679-95. DOI: 10.1016/j.cell.2006.11.001. View

13.

Maris J, Hogarty M, Bagatell R, Cohn S . Neuroblastoma. Lancet. 2007; 369(9579):2106-20. DOI: 10.1016/S0140-6736(07)60983-0. View

14.

Santana V, Furman W, McGregor L, Billups C . Disease control intervals in high-risk neuroblastoma. Cancer. 2008; 112(12):2796-801. DOI: 10.1002/cncr.23507. View

15.

Matthay K, Reynolds C, Seeger R, Shimada H, Adkins E, Haas-Kogan D . Long-term results for children with high-risk neuroblastoma treated on a randomized trial of myeloablative therapy followed by 13-cis-retinoic acid: a children's oncology group study. J Clin Oncol. 2009; 27(7):1007-13. PMC: 2738615. DOI: 10.1200/JCO.2007.13.8925. View

16.

Garaventa A, Parodi S, De Bernardi B, Dau D, Manzitti C, Conte M . Outcome of children with neuroblastoma after progression or relapse. A retrospective study of the Italian neuroblastoma registry. Eur J Cancer. 2009; 45(16):2835-42. DOI: 10.1016/j.ejca.2009.06.010. View

17.

Hurst D, Edmonds M, Welch D . Metastamir: the field of metastasis-regulatory microRNA is spreading. Cancer Res. 2009; 69(19):7495-8. PMC: 2756311. DOI: 10.1158/0008-5472.CAN-09-2111. View

18.

Almeida M, Reis R, Calin G . MicroRNAs and metastases--the neuroblastoma link. Cancer Biol Ther. 2010; 9(6):453-4. DOI: 10.4161/cbt.9.6.11215. View

19.

Guo J, Dong Q, Fang Z, Chen X, Lu H, Wang K . Identification of miRNAs that are associated with tumor metastasis in neuroblastoma. Cancer Biol Ther. 2010; 9(6):446-52. DOI: 10.4161/cbt.9.6.10894. View

20.

Bell E, Chen L, Liu T, Marshall G, Lunec J, Tweddle D . MYCN oncoprotein targets and their therapeutic potential. Cancer Lett. 2010; 293(2):144-57. DOI: 10.1016/j.canlet.2010.01.015. View